Comparative In Vitro Activities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria

被引:50
作者
Citron, Diane M. [1 ]
Tyrrell, Kerin L. [1 ]
Merriam, C. Vreni [1 ]
Goldstein, Ellie J. C. [1 ,2 ]
机构
[1] RM Alden Res Lab, Culver City, CA USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
关键词
FIDAXOMICIN OPT-80; METRONIDAZOLE; RAMOPLANIN; INFECTION; DISEASE; DRUGS;
D O I
10.1128/AAC.06305-11
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The in vitro activities of LFF571, a novel analog of GE2270A that inhibits bacterial growth by binding with high affinity for protein synthesis elongation factor Tu, fidaxomicin, and 10 other antimicrobial agents were determined against 50 strains of Clostridium difficile and 630 other anaerobic and aerobic organisms of intestinal origin. LFF571 possesses potent activity against C. difficile and most other Gram-positive anaerobes (MIC90, <= 0.25 mu g/ml), with the exception of bifidobacteria and lactobacilli. The MIC(90)s for aerobes, including enterococci, Staphylococcus aureus (as well as methicillin-resistant S. aureus [MRSA] isolates), Streptococcus pyogenes, and other streptococci were 0.06, 0.125, 2, and 8 mu g/ml, respectively. Comparatively, fidaxomicin showed variable activity against Gram-positive organisms: MIC(90)s against C. difficile, Clostridium perfringens, and Bifidobacterium spp. were 0.5, <= 0.015, and 0.125 mu g/ml, respectively, but >32 mu g/ml against Clostridium ramosum and Clostridium innocuum. MIC90 for S. pyogenes and other streptococci was 16 and >32 mu g/ml, respectively. LFF571 and fidaxomicin were generally less active against Gram-negative anaerobes.
引用
收藏
页码:2493 / 2503
页数:11
相关论文
共 29 条
[1]   Comparison of clinical and microbiological response to treatment of Clostridium difficile associated disease with metronidazole and vancomycin [J].
Al-Nassir, Wafa N. ;
Sethi, Ajay K. ;
Nerandzic, Michelle M. ;
Bobulsky, Greg S. ;
Jump, Robin L. P. ;
Donskey, Curtis J. .
CLINICAL INFECTIOUS DISEASES, 2008, 47 (01) :56-62
[2]  
[Anonymous], 51 INT C ANT AG CHEM
[3]   Emergence of reduced susceptibility to metronidazole in Clostridium difficile [J].
Baines, Simon D. ;
O'Connor, Rachael ;
Freeman, Jane ;
Fawley, Warren N. ;
Harmanus, Celine ;
Mastrantonio, Paola ;
Kuijper, Ed J. ;
Wilcox, Mark H. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (05) :1046-1052
[4]  
Baron EJ, 2007, MANUAL OF CLINICAL MICROBIOLOGY, 9TH ED, P1
[5]   Biology of Clostridium difficile: Implications for Epidemiology and Diagnosis [J].
Carroll, Karen C. ;
Bartlett, John G. .
ANNUAL REVIEW OF MICROBIOLOGY, VOL 65, 2011, 65 :501-521
[6]   Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria [J].
Citron, Diane M. ;
Warren, Yumi A. ;
Tyrrell, Kerin L. ;
Merriam, Vreni ;
Goldstein, Ellie J. C. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (05) :972-976
[7]   In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria [J].
Citron, DM ;
Merriam, CV ;
Tyrrell, KL ;
Warren, YA ;
Fernandez, H ;
Goldstein, EJC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2334-2338
[8]   DEVELOPMENT OF A RAPID AND EFFICIENT RESTRICTION-ENDONUCLEASE ANALYSIS TYPING SYSTEM FOR CLOSTRIDIUM-DIFFICILE AND CORRELATION WITH OTHER TYPING SYSTEMS [J].
CLABOTS, CR ;
JOHNSON, S ;
BETTIN, KM ;
MATHIE, PA ;
MULLIGAN, ME ;
SCHABERG, DR ;
PETERSON, LR ;
GERDING, DN .
JOURNAL OF CLINICAL MICROBIOLOGY, 1993, 31 (07) :1870-1875
[9]  
CLINICAL LABORATORY STANDARDS INSTITUTE, 2009, M7A8 CLSI
[10]  
CLSI, 2007, M11A7 CLSI